MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative”, "BRTX” or the "Company”) ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil® (remestemcel-L) the first mesenchymal stromal cell ...

Currently, there are only two cell and gene therapies (CGTs) on the market across all gastroenterology (GI) indications. Anterogen's Cupistem, indicated for the treatment of anal fistula in adult ...

The ASX 200 biotech stock notes that HIE is a devastating type of brain injury caused when a baby's brain does not receive ...

Odontogenic myxoma (OM) is a rare benign tumor originating from the odontogenic mesenchyme, characterized by locally aggressive behavior in the jaw bones. We present a case report of a 36-year-old ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing ...

The possibility of gaining access to life-changing stem cell therapy could finally be in reach for many in the region, thanks ...

Nature Cell Co. Ltd. won U.S. FDA breakthrough therapy designation of its autologous adipose-derived mesenchymal stem cell therapy, Jointstem, March 20, becoming the first Korean company to earn the ...

The Mayo Clinic Center for Regenerative Biotherapeutics manufactures a wide range of products for active, early-phase clinical trials.